Report Description Table of Contents How Is the Global Diamond Blackfan Anemia Treatment Market Evolving Through Clinical Management and Emerging Therapies? The Global Diamond-Blackfan Anemia Treatment Market was valued at USD 155.62 million in 2025 and is projected to reach USD 235.36 million by 2032, growing at a CAGR of 6.09% during 2026–2032, according to Strategic Market Research. Corticosteroids, regular red blood cell transfusions, iron chelation therapy, and hematopoietic stem cell transplantation are the principal treatment approaches for Diamond-Blackfan anemia (DBA). According to the U.S. National Library of Medicine, DBA affects approximately 5–7 per million newborns worldwide, with RPS19 gene mutations accounting for approximately 25% of cases. Data from the U.S. Health Resources and Services Administration (HRSA) recorded 90 hematopoietic cell transplants for DBA during 2020–2024, including 25 procedures in 2024. Stem cell transplantation and transfusion-dependent care remain important components of DBA treatment. A 2026 Eurocord/EBMT study evaluated 41 children who underwent umbilical cord blood transplantation between 1994 and 2023, reporting five-year overall survival rates of 100% for 20 related-donor recipients and 66% for 21 unrelated-donor recipients. Separately, a 2024 NIH/NHLBI study evaluated eltrombopag in 15 transfusion-dependent DBA patients requiring red blood cell transfusions every 3–5 weeks. One patient achieved sustained hemoglobin improvement and a reduction in transfusion frequency exceeding 50%, indicating limited treatment response in the study population. Gene therapy development and investigational drug research are shaping the Diamond-Blackfan anemia treatment pipeline. Apriligen is developing APR-2020, an investigational autologous gene therapy targeting RPS19-deficient DBA, with clinical enrollment initiated. Meanwhile, a 2026 NIH/NHLBI study of bitopertin involving 15 transfusion-dependent adults reported no patients meeting the primary response criteria after eight months, with transfusion requirements remaining unchanged. In April 2026, Fulcrum Therapeutics notified CAMP4 Therapeutics of its decision to terminate their DBA program licensing agreement. These developments highlight ongoing clinical investigation alongside efficacy limitations and changes in the competitive landscape of DBA treatment. Which Treatment Categories, Patient Groups, and Regional Markets Are Leading the Diamond Blackfan Anemia Treatment Industry? By Treatment Type: Transfusions Lead Care as Gene Therapies Advance Leading Subsegment: Blood Transfusion Therapy Blood Transfusion Therapy dominates the Diamond-Blackfan Anemia Treatment Market, accounting for the largest share of 32%, valued at USD 49.80 million in 2025, and is projected to grow at a CAGR of 5.50% during 2026–2032. Red blood cell transfusions remain a primary life-sustaining intervention for patients with inadequate red blood cell production, particularly those who fail to respond to corticosteroids or require long-term hematological support. Regular transfusions help maintain hemoglobin levels, manage severe anemia, and reduce complications associated with chronic erythrocyte deficiency. Fastest-Growing Subsegment: Emerging Gene Therapies Emerging gene therapies represent an estimated 1% share of the global Diamond-Blackfan Anemia Treatment Market, valued at USD 1.56 million in 2025, and are projected to register the fastest CAGR of 24.00% during 2026–2032. Gene-based approaches are advancing as potential one-time, curative interventions by targeting the underlying genetic abnormalities responsible for impaired red blood cell production. Continued progress in gene correction, hematopoietic stem cell research, and clinical development could reduce long-term dependence on corticosteroids, repeated blood transfusions, and allogeneic stem cell transplantation. By Patient Age Group: Pediatric Care Dominates Lifelong Treatment Requirements Leading and Fastest-Growing Subsegment: Pediatric Patients Pediatric Patients dominate with a 78% market share, representing USD 121.38 million in 2025, and are projected to expand at a CAGR of 6.30% during 2026–2032. Approximately 90% of Diamond-Blackfan anemia cases are diagnosed during the first year of life, with many patients presenting symptoms within six months of birth. The disorder affects an estimated 5–10 infants per million live births, creating a concentrated population requiring early hematologic evaluation, corticosteroid therapy, transfusions, and specialized follow-up. Pediatric treatment expenditure is influenced by repeated transfusion requirements, growth-related corticosteroid complications, genetic testing, and eligibility assessments for curative transplantation. Fastest-Growing Subsegment: Pediatric Patients Pediatric patients dominate the Diamond-Blackfan Anemia Treatment Market, accounting for a 78% market share, valued at USD 121.38 million in 2025, and are projected to grow at a CAGR of 6.30% during 2026–2032. As Diamond-Blackfan Anemia is typically diagnosed during infancy or early childhood, pediatric patients require specialized, multidisciplinary care involving corticosteroid therapy, regular red blood cell transfusions, iron chelation, and hematopoietic stem cell transplantation. Early diagnosis, continuous hematological monitoring, and long-term treatment management reinforce the predominance of pediatric patients in DBA treatment. By End User: Hospitals Lead as Specialized Transplant Centers Expand Leading Subsegment: Hospitals Hospitals dominate the global Diamond Blackfan Anemia Treatment Market, accounting for the largest 61% market share, valued at USD 94.93 million in 2025, and are projected to grow at a CAGR of 5.50% during 2026–2032. Hospitals serve as primary treatment centers for patients with Diamond Blackfan Anemia, providing specialized hematological diagnosis, corticosteroid therapy, regular red blood cell transfusions, iron chelation therapy, and hematopoietic stem cell transplantation. The availability of multidisciplinary pediatric hematology teams, transfusion facilities, and advanced transplant infrastructure supports their leading position. Fastest-Growing Subsegment: Stem Cell Transplant Centers Stem Cell Transplant Centers accounted for 13% of the global Diamond-Blackfan Anemia Treatment Market, valued at USD 20.23 million in 2025, and are projected to register the fastest CAGR of 8.40% during 2026–2032. Specialized transplant centers provide the only established curative treatment for Diamond-Blackfan Anemia through allogeneic hematopoietic stem cell transplantation, replacing defective bone marrow with healthy donor stem cells. Expanding transplant eligibility, improved donor matching, and advances in supportive care are expected to strengthen treatment access and clinical outcomes. By Geography: North America Leads as Asia-Pacific Expands Specialized Care Leading Region: North America North America dominated the Diamond-Blackfan Anemia Treatment Market with a 39% share, valued at USD 60.69 million in 2025, and is projected to grow at a CAGR of 5.40% during 2026–2032. The region’s leadership is supported by established pediatric hematology centers, standardized diagnostic protocols, and individualized treatment strategies involving corticosteroid therapy, chronic blood transfusions, and hematopoietic stem cell transplantation. Expanding access to genetic testing, specialized clinical care, and ongoing research into emerging gene therapies further supports treatment adoption and long-term disease management across the United States and Canada. Fastest-Growing Region: Asia-Pacific Asia-Pacific Diamond-Blackfan Anemia Treatment Market accounted for a 24% global market share, valued at USD 37.35 million in 2025, and is projected to register the fastest regional CAGR of 7.60% during 2026–2032. Treatment practices across the region are gradually shifting from conventional supportive care toward standardized clinical protocols, including corticosteroid therapy, regular red blood cell transfusions, iron chelation, and hematopoietic stem cell transplantation. Improving access to specialized hematology centers, genetic diagnostic services, and pediatric treatment facilities is supporting earlier diagnosis and more structured long-term disease management. What Emerging Treatment Options Are Transforming the Therapeutic Landscape of Diamond Blackfan Anemia? 1. RPS19-Targeted Gene Therapy: Apriligen is developing APR-2020, an investigational lentiviral gene therapy designed for patients with RPS19-deficient Diamond Blackfan Anemia. The treatment involves collecting a patient's hematopoietic stem cells, introducing a functional RPS19 gene using a modified viral vector, and returning the treated cells following bone marrow conditioning. The objective is to restore red blood cell production and potentially eliminate long-term transfusion requirements. The Phase 1 clinical trial NCT07476183 is recruiting participants, with the trial record covering ages 2–25 years. Its initial assessment focuses on safety, treatment tolerability, hematologic recovery, and transfusion independence. Successful clinical development could establish a highly specialized treatment pathway for genetically confirmed RPS19-related DBA. 2. GATA1-Based Gene Therapy: Researchers associated with Boston Children's Hospital and Harvard Medical School are investigating a lentiviral approach that delivers the GATA1 gene to improve red blood cell development. Unlike therapies targeting individual ribosomal protein mutations, GATA1-based treatment addresses a common downstream mechanism affecting erythroid maturation across multiple DBA genetic subtypes. Published preclinical research demonstrated improved red blood cell production in patient-derived experimental systems using controlled GATA1 expression. The technology could eventually extend gene therapy eligibility beyond patients carrying specific mutations, although clinical safety and effectiveness remain to be established in human trials. 3. Eltrombopag: Eltrombopag, a thrombopoietin receptor agonist, is being investigated for patients with corticosteroid-resistant or corticosteroid-intolerant DBA. The medication acts through pathways involved in hematopoietic cell activity and may help improve red blood cell production in selected patients. The NIH-sponsored clinical study NCT04269889, listed as completed, evaluated eltrombopag in refractory DBA. Establishing a meaningful hematologic response could create an oral treatment alternative for eligible patients and potentially reduce the frequency of blood transfusions and associated iron chelation requirements. 4. Trifluoperazine and Other Investigational Drug Approaches Trifluoperazine, an established medication investigated for potential hematologic effects, has been studied as a repurposed treatment for transfusion-dependent DBA. The Phase 1/2 study NCT03966053, supported by CAMP4 Therapeutics, examined its safety in adult patients with chronic transfusion requirements. Repurposed pharmacological approaches offer potential development advantages through existing drug-manufacturing infrastructure and previously characterized safety profiles. However, DBA-specific clinical benefits require evidence of sustained red blood cell improvement and acceptable long-term tolerability. 5. Reduced-Toxicity Stem Cell Transplantation Advancements in hematopoietic stem cell transplantation conditioning are intended to make potentially curative treatment accessible to a wider population of eligible DBA patients. The BMT CTN 1904 clinical protocol investigates treosulfan-based conditioning, incorporating agents such as fludarabine and antithymocyte globulin for inherited bone marrow failure disorders, including DBA. These protocols seek to support successful donor stem cell engraftment while limiting complications associated with intensive conditioning. Improvements in transplant safety could strengthen the use of HSCT among children and patients requiring prolonged transfusion support. 6. Bitopertin: Targeting Heme Production Pathways Bitopertin, investigated in collaboration with researchers from the National Institutes of Health and Disc Medicine, represents another pharmacological research direction. The drug inhibits glycine transporter 1 (GlyT1), influencing the availability of glycine for heme synthesis in developing red blood cells. A clinical study published in September 2026 investigated bitopertin in patients with steroid-relapsed or refractory DBA. This approach provides an opportunity to explore targeted regulation of red blood cell production, although its future clinical role depends on confirmed efficacy and safety outcomes. Which Leading Companies Are Advancing the Diamond Blackfan Anemia Treatment Market Through Specialized Therapeutic Technologies? Apriligen Apriligen is a notable emerging company in the Diamond Blackfan Anemia Treatment Market, particularly through its investigational APR-2020 lentiviral gene therapy program, designed to address RPS19-related Diamond Blackfan Anemia. The technology uses genetically modified autologous hematopoietic stem cells to introduce a functional RPS19 gene, potentially restoring red blood cell production and reducing long-term transfusion dependence. RPS19 mutations account for approximately 25% of genetically characterized DBA cases, making them an important target for precision genetic therapies. The supplied clinical development information identifies Phase 1 trial NCT07476183, covering patients aged 2–25 years. APR-2020's commercial potential is linked to clinical safety, durable hematologic recovery, and successful regulatory approval. Apriligen's leadership is therefore associated with DBA-focused therapeutic innovation rather than demonstrated commercial revenue. Other Companies and Their Roles: Novartis AG: Markets eltrombopag, a thrombopoietin receptor agonist investigated for refractory DBA, alongside established iron chelation products used to manage transfusion-related iron overload. Pfizer Inc.: Operates in hematology and rare-disease therapeutics, although the supplied information does not identify a dedicated, commercially approved DBA treatment. Bristol Myers Squibb: Develops hematology therapies, including erythroid maturation technologies, offering scientific relevance to anemia treatment without an established DBA-specific indication. AstraZeneca: Maintains broader pharmaceutical and rare-disease capabilities, although a direct commercial DBA-specific therapy or clinical development program is not established in the supplied information. Analyst Commentary: How Will Genetic Therapies and Safer Transplantation Shape Treatment Adoption? The Diamond Blackfan Anemia Treatment Market presents significant opportunities for therapies that reduce lifelong transfusion dependence and improve sustained red blood cell production. The greatest commercial potential lies in RPS19-targeted gene therapy, mutation-independent genetic approaches, and safer stem cell transplantation. Future treatment adoption will depend on durable clinical outcomes, expanded patient eligibility, regulatory approvals, and reimbursement accessibility, particularly for high-cost curative interventions. Diamond Blackfan Anemia Treatment Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 155.62 Million Revenue Forecast in 2032 USD 235.36 Million Overall Growth Rate CAGR of 6.09% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million, CAGR (2026 – 2032) Segmentation By Treatment Type, By Patient Age Group, By End User, By Geography By Treatment Type Corticosteroid Therapy, Blood Transfusion Therapy, Hematopoietic Stem Cell Transplantation, Iron Chelation Therapy, Emerging Gene Therapies By Patient Age Group Pediatric Patients, Adult Patients By End User Hospitals, Specialty Hematology Clinics, Stem Cell Transplant Centers By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Recurring transfusion and iron chelation requirements, expanding access to specialized hematology care, improved genetic diagnosis, advances in stem cell transplantation, development of gene therapies targeting transfusion dependence Customization Option Available upon request Frequently Asked Question About This Report Q1. Why does long-term supportive care remain important to market demand? A1. Patients who do not respond adequately to corticosteroids may require repeated red blood cell transfusions. This creates continuing requirements for transfusion services and iron chelation medicines. Blood transfusion therapy accounts for the largest estimated treatment share at 32% in 2025. Q2. What innovations could reshape the industry over the coming years? A2. Research is focused on gene therapies that restore red blood cell production and transplant protocols designed to reduce treatment toxicity. APR-2020 targets patients with RPS19-related disease. These approaches could reduce transfusion dependence, but wider adoption depends on demonstrated safety and durable clinical benefit. Q3. Which patient group accounts for the largest market share? A3. Pediatric patients account for an estimated 78% share in 2025 because diagnosis commonly occurs during infancy or early childhood. Their care involves medication, transfusions and specialist monitoring. Early treatment needs make pediatric hematology services central to spending and treatment development. Q4. What are the biggest challenges affecting market expansion? A4. Emerging treatments must demonstrate sustained improvements in red blood cell production. Some investigated medicines have shown limited or no meaningful response in small studies. For advanced interventions, patient eligibility and reimbursement access also influence how many people can receive treatment. Q5. Which healthcare providers offer growing opportunities in the market? A5. Hospitals lead with an estimated 61% share in 2025 through transfusion services and multidisciplinary care. Stem cell transplant centers are projected to grow fastest among end users at 8.40% annually during 2026–2032. Improved donor matching and conditioning protocols could expand access for eligible patients. Q6. How is regional access influencing industry growth? A6. North America leads through established hematology programs and advanced transplantation services. Asia-Pacific is projected to record the fastest regional CAGR of 7.60% during 2026–2032. Expanding genetic testing and specialist care in China, Japan, India and South Korea are important factors behind that outlook. Sources: U.S. National Library of Medicine – Diamond–Blackfan Anemia Affects Approximately 5–7 per Million Newborns Worldwide, With RPS19 Mutations Accounting for Approximately 25% of Cases MedlinePlus Genetics – Diamond–Blackfan Anemia: Frequency and Genetic Characteristics U.S. HRSA – 90 Hematopoietic Cell Transplants for DBA Were Reported in the United States During 2020–2024, Including 25 Procedures in 2024 HRSA – Hematopoietic Cell Transplants by Year and Specific Disease: Table 10 NIH / NHLBI – A 2024 Eltrombopag Study Treated 15 DBA Patients Requiring Transfusions Every 3–5 Weeks, With One Patient Achieving a Greater Than 50% Reduction in Transfusion Frequency PubMed Central – Treatment of Refractory or Relapsed Diamond–Blackfan Anemia With Eltrombopag Apriligen – Develops APR-2020, an Investigational Autologous Lentiviral Gene Therapy for RPS19-Deficient DBA, With Clinical Enrollment Underway Apriligen – APR-2020 Gene Therapy Program and Clinical Development Disc Medicine – Identifies Bitopertin in Its DBA Development Pipeline Through an Investigator-Initiated Study With NIH Disc Medicine – Pipeline: Bitopertin Research in Diamond–Blackfan Anemia Novartis – Provided Research Support for the NIH / NHLBI Eltrombopag Study in Refractory or Relapsed DBA PubMed Central – Eltrombopag DBA Study: NIH and Novartis Research Support ClinicalTrials.gov – Apriligen’s Phase I APR-2020 Trial Covers Patients Aged 2–25 Years and Lists an Estimated Enrollment of Four Participants ClinicalTrials.gov – NCT07476183: APR-2020 in RPS19-Deficient Diamond–Blackfan Anemia U.S. National Library of Medicine–Indexed Research – Regulated GATA1 Gene Delivery Improved Red Blood Cell Production in DBA Models and Diverse Patient-Derived Samples PubMed – Regulated GATA1 Expression as a Universal Gene Therapy for Diamond–Blackfan Anemia U.S. National Cancer Institute – Phase II BMT CTN 1904 Evaluates Treosulfan, Fludarabine, and Rabbit Antithymocyte Globulin Before Transplantation, Including Eligible DBA Patients NCI – BMT CTN 1904 / NCT04965597: Treosulfan-Based Transplant Conditioning ClinicalTrials.gov – The Phase I/II Trifluoperazine DBA Study Enrolled Two Participants and Was Terminated Following Slow Recruitment Associated With COVID-19 Travel Restrictions ClinicalTrials.gov – NCT03966053: Trifluoperazine in Transfusion-Dependent DBA NIH / NHLBI – A 2026 Bitopertin Study in 15 Transfusion-Dependent Adults With DBA Found No Participants Meeting Response Criteria at the Eight-Month Primary Endpoint PubMed Central – First Clinical Trial of Bitopertin for Steroid-Relapsed or Refractory Diamond–Blackfan Anemia Eurocord / EBMT, Indexed by the U.S. National Library of Medicine – A 2026 Study Evaluated 41 Children Receiving Cord Blood Transplants, Reporting Five-Year Survival of 100% for Related-Donor and 66% for Unrelated-Donor Recipients PubMed – Umbilical Cord Blood Transplantation in Children With Diamond–Blackfan Anemia Fulcrum Therapeutics / CAMP4 Therapeutics – Fulcrum Gave Notice on April 23, 2026, to Terminate Its License Covering CAMP4’s DBA Program U.S. SEC – Fulcrum Form 8-K: Termination Notice for the CAMP4 Diamond–Blackfan Anemia License Table of Contents - Global Diamond Blackfan Anemia Treatment Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Patient Age Group, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Patient Age Group, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Patient Age Group, and End User Investment Opportunities in the Diamond Blackfan Anemia Treatment Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in RPS19-Targeted Gene Therapy, Blood Transfusion Management, Iron Chelation Therapy, Hematopoietic Stem Cell Transplantation, and Emerging Pharmacological Treatments Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Diamond Blackfan Anemia Treatment in Lifelong Anemia Management, Transfusion Dependence Reduction, and Genetic Therapy Development Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approval, Clinical Evidence, and Rare-Disease Treatment Accessibility Role of Corticosteroid Therapy, Blood Transfusions, Iron Chelation, and Hematopoietic Stem Cell Transplantation in Market Expansion Gene Therapy Development, Long-Term Treatment Monitoring, and Management of Transfusion-Related Iron Overload Global Diamond Blackfan Anemia Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Corticosteroid Therapy Blood Transfusion Therapy Hematopoietic Stem Cell Transplantation Iron Chelation Therapy Emerging Gene Therapies Market Analysis by Patient Age Group: Pediatric Patients Adult Patients Market Analysis by End User: Hospitals Specialty Hematology Clinics Stem Cell Transplant Centers Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Diamond Blackfan Anemia Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Patient Age Group, and End User Country-Level Breakdown: United States Canada Mexico Europe Diamond Blackfan Anemia Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Patient Age Group, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Diamond Blackfan Anemia Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Patient Age Group, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Diamond Blackfan Anemia Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Patient Age Group, and End User Country-Level Breakdown: Brazil Mexico Argentina Rest of Latin America Middle East & Africa Diamond Blackfan Anemia Treatment Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Patient Age Group, and End User Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Apriligen Novartis AG Pfizer Inc. Bristol Myers Squibb AstraZeneca Disc Medicine, Inc. Fulcrum Therapeutics CAMP4 Therapeutics Rocket Pharmaceuticals Competitive Landscape and Strategic Insights Benchmarking Based on Treatment Portfolio, Rare-Disease Research Capabilities, Clinical Development Progress, Genetic Therapy Platforms, and Regional Presence Clinical Trial Progress and Regulatory Development Analysis RPS19-Targeted Gene Therapy Development and Precision Treatment Positioning Blood Transfusion, Corticosteroid, and Iron Chelation Treatment Competitiveness Hematopoietic Stem Cell Transplantation, Conditioning Protocols, and Long-Term Patient Management Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Treatment Type, Patient Age Group, End User, and Region (2026–2032) Regional Market Breakdown by Treatment Type, Patient Age Group, and End User (2026–2032) Competitive Benchmarking of Leading Vendors Clinical Development, Regulatory Approval, and Treatment Accessibility Analysis Emerging Treatment Trends Across Corticosteroid Therapy, Blood Transfusion Therapy, Iron Chelation, Hematopoietic Stem Cell Transplantation, and Gene Therapy List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Patient Age Group, and End User (2025 vs. 2032) Global Diamond Blackfan Anemia Treatment Ecosystem and Value Chain Analysis